News Quantified

XBIT – xbiotech inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

XBiotech (NASDAQ:XBIT) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

XBiotech (NASDAQ:XBIT) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

XBiotech (NASDAQ:XBIT) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.

XBiotech (NASDAQ:XBIT) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.

XBiotech (NASDAQ:XBIT) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.

Form 10-Q XBiotech Inc. For: Sep 30

Form 4 XBiotech Inc. For: Oct 01 Filed by: Rademaker Craig Evan

Form 4 XBiotech Inc. For: Oct 01 Filed by: Soffer David Spencer

Form 4 XBiotech Inc. For: Oct 01 Filed by: Kuendig Thomas Martin

Form 4 XBiotech Inc. For: Oct 01 Filed by: Troy Tevi David

Top News Gainers

12/7 XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen 75.4%

1/14 XBiotech Commences Tender Offer to Purchase up to $420,000,000 of its Shares 15.9%

11/13 XBiotech Inc (NASDAQ: XBIT) had its "overweight" rating re-affirmed by analysts at Piper Jaffray Companies. They now have a $16.00 price target on the stock, up previously from $13.00. 14.6%

3/16 Q4/2019 12/31/2019 EPS 14.820 ZacksConsensus N/A ActVsEst N/A - N/A 13.1%

4/3 XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered Patients 12.2%

11/19 XBiotech Announces Rapid Enrollment for its Randomized Multi-Center Clinical Study for Bermekimab in Patients with Hidradenitis Suppurativa 10.4%

9/21 XBiotech Inc (NASDAQ: XBIT) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 7.6%

3/19 Form 4/A XBiotech Inc. For: Feb 12 Filed by: SIMARD JOHN 6.7%

6/6 Form 4 XBiotech Inc. For: Jun 04 Filed by: RENNES FONDATION 6.1%

2/13 Form SC TO-I/A XBiotech Inc. Filed by: XBiotech Inc. 5.0%

Top News Decliners

5/30 Form 8-K XBiotech Inc. For: May 30 -20.7%

1/14 Form SC TO-I XBiotech Inc. Filed by: XBiotech Inc. -17.9%

2/13 Form 4 XBiotech Inc. For: Feb 03 Filed by: RENNES FONDATION -11.4%

12/30 Form 8-K XBiotech Inc. For: Dec 30 -8.9%

3/20 XBiotech Inc (NASDAQ: XBIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -8.7%

10/2 XBiotech Announces First Patient in Clinical Study to Evaluate Bermekimab in Systemic Sclerosis -8.5%

6/3 Form 8-K XBiotech Inc. For: May 31 -6.6%

7/11 Dr. Seth Forman to Chair XBiotech’s Second Phase 2 Study of Bermekimab in Atopic Dermatitis -5.9%

2/1 XBiotech Inc (NASDAQ: XBIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.4%

11/12 Form 10-Q XBiotech Inc. For: Sep 30 -4.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day